BMO Capital Downgrades Pfizer (PFE) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Argus Downgrades Pfizer (PFE) to Hold
November 2, 2016 7:54 AM EDTArgus downgraded Pfizer (NYSE: PFE) from Buy to Hold on a weaker outlook.
The analyst no longer expect PFE to achieve their former target price of $39 given recent pipeline setbacks, prospects for increased competition, and managements decision to shelve its business separation... More
Pfizer (PFE) Misses Q3 EPS by 1c
November 1, 2016 6:46 AM EDTPfizer (NYSE: PFE) reported Q3 EPS of $0.61, $0.01 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $13.05 billion versus the consensus estimate of $13.05 billion.
Prevnar revenue was $1.54 billion, versus $1.46 billion expectedIbrance revenue was $550 million, versus $548.4 million expected.EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our business continues to perform well as demonstrated by the quarters financial results. Our Innovative Health business executed strongly behind the latest product launches, and our two recent acquisitions -- Medivation and Anacor -- are providing new near-term... More
